01

ABBVIE

U.S.A

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-03-24

MEMANTINE HYDROCHLORIDE

US Patent Number : 8039009

Drug Substance Claim :

Drug Product Claim :

Application Number : 22525

Patent Use Code : U-539

Patent Use Description : TREATMENT OF MODERATE ...

Patent Expiration Date : 2029-03-24

Product Web Link

Corporate PDF

02

ABBVIE

U.S.A

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-03-24

MEMANTINE HYDROCHLORIDE

US Patent Number : 8039009

Drug Substance Claim :

Drug Product Claim :

Application Number : 22525

Patent Use Code : U-539

Patent Use Description : TREATMENT OF MODERATE ...

Patent Expiration Date : 2029-03-24

Product Web Link

Corporate PDF

03

ABBVIE

U.S.A

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-11-22

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

US Patent Number : 8173708

Drug Substance Claim :

Drug Product Claim :

Application Number : 206439

Patent Use Code : U-1641

Patent Use Description : MEMANTINE HCL/DONEPEZI...

Patent Expiration Date : 2025-11-22

Product Web Link

Corporate PDF

04

ABBVIE

U.S.A

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-11-22

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

US Patent Number : 8173708

Drug Substance Claim :

Drug Product Claim :

Application Number : 206439

Patent Use Code : U-1641

Patent Use Description : MEMANTINE HCL/DONEPEZI...

Patent Expiration Date : 2025-11-22

Product Web Link

Corporate PDF

05

ABBVIE

U.S.A

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-11-22

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

US Patent Number : 8362085

Drug Substance Claim :

Drug Product Claim :

Application Number : 206439

Patent Use Code : U-1641

Patent Use Description : MEMANTINE HCL/DONEPEZI...

Patent Expiration Date : 2025-11-22

Product Web Link

Corporate PDF

06

ABBVIE

U.S.A

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-03-24

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

US Patent Number : 8039009

Drug Substance Claim :

Drug Product Claim :

Application Number : 206439

Patent Use Code : U-1641

Patent Use Description : MEMANTINE HCL/DONEPEZI...

Patent Expiration Date : 2029-03-24

Product Web Link

Corporate PDF

07

ABBVIE

U.S.A

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-12-05

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

US Patent Number : 8058291

Drug Substance Claim :

Drug Product Claim :

Application Number : 206439

Patent Use Code : U-1641

Patent Use Description : MEMANTINE HCL/DONEPEZI...

Patent Expiration Date : 2029-12-05

Product Web Link

Corporate PDF

08

ABBVIE

U.S.A

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-11-22

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

US Patent Number : 8338486

Drug Substance Claim :

Drug Product Claim :

Application Number : 206439

Patent Use Code : U-1641

Patent Use Description : MEMANTINE HCL/DONEPEZI...

Patent Expiration Date : 2025-11-22

Product Web Link

Corporate PDF

09

ABBVIE

U.S.A

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-12-05

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

US Patent Number : 8058291

Drug Substance Claim :

Drug Product Claim :

Application Number : 206439

Patent Use Code : U-1641

Patent Use Description : MEMANTINE HCL/DONEPEZI...

Patent Expiration Date : 2029-12-05

Product Web Link

Corporate PDF

10

ABBVIE

U.S.A

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-11-22

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

US Patent Number : 8283379

Drug Substance Claim :

Drug Product Claim :

Application Number : 206439

Patent Use Code : U-1641

Patent Use Description : MEMANTINE HCL/DONEPEZI...

Patent Expiration Date : 2025-11-22

Product Web Link

Corporate PDF

Memantine Hydrochloride

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

64 API Suppliers

34 USDMF

11 JDMF

15 EU WC

26 KDMF

30 NDC API

35 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

4 Drugs in Development

INTERMEDIATES

14 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

480 FDF Dossiers

125 FDA Orange Book

244 Europe

11 Canada

14 Australia

9 South Africa

77 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 10MG

TABLET;ORAL - 5MG

CAPSULE, EXTENDED RELEASE;ORAL - 14MG

CAPSULE, EXTENDED RELEASE;ORAL - 21MG

CAPSULE, EXTENDED RELEASE;ORAL - 28MG

CAPSULE, EXTENDED RELEASE;ORAL - 7MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Minakem

2 Rochem International Inc

8 SPI Pharma

2 Seqens

8 DKSH

1 Pharm-RX Chemical

7 Faran Shimi Pharmaceutical

5 Boai NKY Pharmaceuticals Ltd

1 Chynops Pharma

16 Gangwal Healthcare

8 Nanjing Well Pharmaceutical

1 Pfanstiehl

4 ACG Worldwide

8 Actylis

1 Aeon Procare

1 Alcedo Pharmachem

10 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

1 Avesta Pharma

26 BASF

1 Bioplus Life Sciences

2 Clariant

11 Corel Pharma Chem

7 DFE Pharma

2 Finar

9 Gangwal Chemicals

7 Ideal Cures Pvt Ltd

4 Ingredion Pharma Solutions

37 Kerry

4 Kima Chemical

6 Lonza Capsugel

12 Microlex e.U

1 NEWEDGE Overseas

2 Nomisma Healthcare

3 Novo Excipients

4 Pharmatrans-Sanaq

8 Pluviaendo

5 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

2 Qualicaps

27 Roquette

8 Seppic

6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

12 Sigachi Industries

3 The Dow Chemical Company

CAPSULE, EXTENDED RELEASE;ORAL - 7MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons